Wells Fargo & Company Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price

PTC Therapeutics (NASDAQ:PTCT) had its target price increased by Wells Fargo & Company from $109.00 to $112.00 in a research note released on Friday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Cantor Fitzgerald boosted their target price on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Wall Street Zen downgraded shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Weiss Ratings raised shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. Morgan Stanley lifted their price objective on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Barclays lifted their price objective on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $95.64.

PTC Therapeutics Stock Down 7.0%

PTCT opened at $59.97 on Friday. The business has a fifty day moving average of $65.36 and a 200 day moving average of $70.78. PTC Therapeutics has a 52-week low of $58.80 and a 52-week high of $90.87. The stock has a market cap of $5.01 billion, a P/E ratio of -42.84, a PEG ratio of 1.95 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.76). The business had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The firm’s revenue was up 69.6% compared to the same quarter last year. Equities analysts anticipate that PTC Therapeutics will post 1.19 EPS for the current fiscal year.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, Director Michael Schmertzler sold 12,500 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $72.94, for a total transaction of $911,750.00. Following the transaction, the director directly owned 1,349,094 shares in the company, valued at $98,402,916.36. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 2,813 shares of PTC Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.57, for a total value of $204,139.41. Following the sale, the vice president directly owned 105,272 shares of the company’s stock, valued at approximately $7,639,589.04. This trade represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,370 shares of company stock worth $5,322,261 in the last ninety days. 5.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors have recently made changes to their positions in PTCT. BlackRock Inc. bought a new stake in shares of PTC Therapeutics in the second quarter valued at about $1,139,089,000. Jupiter Topco LLC purchased a new stake in PTC Therapeutics in the second quarter worth about $590,182,000. Janus Henderson Group PLC grew its holdings in PTC Therapeutics by 48.3% during the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock worth $489,997,000 after acquiring an additional 2,342,101 shares in the last quarter. Wellington Management Group LLP grew its holdings in PTC Therapeutics by 4.7% during the 2nd quarter. Wellington Management Group LLP now owns 4,128,273 shares of the biopharmaceutical company’s stock worth $336,743,000 after acquiring an additional 185,663 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in PTC Therapeutics by 31.8% during the 1st quarter. Bank of America Corp DE now owns 1,886,841 shares of the biopharmaceutical company’s stock worth $128,550,000 after acquiring an additional 455,284 shares in the last quarter.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.